Your browser doesn't support javascript.
loading
Association between allergic conditions and COVID-19 susceptibility and outcomes.
Chen, Chao; Song, Xue; Murdock, Dana J; Marcus, Andrea; Hussein, Mohamed; Jalbert, Jessica J; Geba, Gregory P.
Afiliação
  • Chen C; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Song X; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Murdock DJ; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Marcus A; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Hussein M; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Jalbert JJ; Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
  • Geba GP; Regeneron Pharmaceuticals, Inc., Tarrytown, New York. Electronic address: gregory.geba@regeneron.com.
Ann Allergy Asthma Immunol ; 132(5): 637-645.e7, 2024 May.
Article em En | MEDLINE | ID: mdl-38242353
ABSTRACT

BACKGROUND:

The relationship between underlying type 2 inflammation and immune response to COVID-19 is unclear.

OBJECTIVE:

To assess the relationships between allergic conditions and COVID-19 susceptibility and outcomes.

METHODS:

In the Optum database, adult patients with and without major allergic conditions (asthma, atopic dermatitis [AD], allergic rhinitis, food allergy, anaphylaxis, or eosinophilic esophagitis) and patients with and without severe asthma/AD were identified. Adjusted incidence rate ratios for COVID-19 were compared among patients with vs without allergic conditions or severe asthma/AD vs non-severe asthma/AD during April 1, 2020, to December 31, 2020. Among patients with COVID-19, adjusted hazard ratios (aHRs) of 30-day COVID-19-related hospitalization/all-cause mortality were estimated for the same comparisons during April 1, 2020, to March 31, 2022.

RESULTS:

Patients with (N = 1,273,231; asthma, 47.2%; AD, 1.5%; allergic rhinitis, 58.6%; food allergy, 5.1%; anaphylaxis, 4.1%; eosinophilic esophagitis, 0.9%) and without allergic conditions (N = 2,278,571) were identified. Allergic conditions (adjusted incidence rate ratios [95% CI], 1.22 [1.21-1.24]) and asthma severity (1.12 [1.09-1.15]) were associated with increased incidence of COVID-19. Among patients with COVID-19 (patients with [N = 261,076] and without allergic conditions [N = 1,098,135] were matched on age, sex, region, index month), having an allergic condition had minimal impact on 30-day COVID-19-related hospitalization/all-cause mortality (aHR [95% CI] 0.96 [0.95-0.98]) but was associated with a lower risk of mortality (0.80 [0.78-0.83]). Asthma was associated with a higher risk of COVID-19-related hospitalization/all-cause mortality vs non-asthma allergic conditions (aHR [95% CI], 1.27 [1.25-1.30]), mostly driven by higher hospitalization.

CONCLUSION:

Allergic conditions were associated with an increased risk of receiving COVID-19 diagnosis but reduced mortality after infection.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 / Hospitalização Tipo de estudo: Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 / Hospitalização Tipo de estudo: Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article